Metrion Biosciences Welcomes New CEO Lee Patterson
Metrion Biosciences appoints Lee Patterson as CEO, succeeding Dr. Andrew S., to drive growth and innovation.
Metrion Biosciences, a leader in ion channel screening and preclinical contract research, has appointed Lee Patterson as its new CEO, effective December 2, 2024. With extensive experience in life sciences and contract research organizations, Patterson is set to drive the company's ambitious growth strategy.
Under his leadership, Metrion aims to enhance its specialist services and strengthen its global presence. This transition comes as Dr. Andrew S. steps down after five impactful years as CEO, marking a new chapter for the company’s strategic direction and innovation in the field.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Más de Pharma News
Todos los artículos →
Medicus Pharma presenta al FDA el protocolo combinado de fase 2b/3 para Teverelix
Fresenius Kabi recibe una carta de advertencia de la FDA tras fallos en la investigación del procesamiento aséptico en la planta de Melrose Park
Discussion